Belimumab bei einer 16-jährigen Patientin mit juvenilem systemischem Lupus erythematodes

D. Barthel; G. Horneff

doi:10.1055/s-0037-1618351

Arthritis und Rheuma, Inhaltsverzeichnis

Arthritis und Rheuma 2015; 35(01): 56-58
DOI: 10.1055/s-0037-1618351

Kasuistik

Schattauer GmbH

Belimumab bei einer 16-jährigen Patientin mit juvenilem systemischem Lupus erythematodes

Authors

D. Barthel

¹Asklepios Klinik Sankt Augustin, Zentrum für Allgemeine Pädiatrie und Neonatologie, St. Augustin
G. Horneff

¹Asklepios Klinik Sankt Augustin, Zentrum für Allgemeine Pädiatrie und Neonatologie, St. Augustin

Abstract

als PDF herunterladen

PDF (118 kb)

Referenzen

Literatur
1 Falcini F, Capannini S, Martini G. et al Mycophenolate mofetil for the treatment of juvenile onset SLE: a multicenter study. Lupus 2009; 18 (02) 139-143.
2 Furie R, Petri M, Zamani O, Cervera R. et al BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63 (12) 3918-3930.
3 Ginzler EM, Wallace DJ, Merrill JT. et al Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. Rheumatol 2014; 41 (02) 300-309.
4 Gurevitz SL, Snyder JA, Wessel EK. et al Systemic lupus erythematosus: a review of the disease and treatment options. Consult Pharm 2013; 28 (02) 110-121.
5 Hiraki LT, Benseler SM, Tyrrell PN. et al Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr 2008; 152 (04) 550-556.
6 Hoffman IE, Lauwerys BR, De Keyser F. et al Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis 2009; 68 (03) 412-415.
7 Merrill JT, Neuwelt CM, Wallace DJ. et al Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233.
8 Mosca M, Bombardieri S. Disease-specific quality indicators, guidelines, and outcome measures in systemic lupus erythematosus (SLE). Clin Exp Rheumatol 2007; 25 47 (6 Supp) 107-113.
9 Rovin BH, Furie R, Latinis K. et al LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64 (04) 1215-1226.
10 Strand V, Levy RA, Cervera R. et al BLISS-52 and -76 Study Groups. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis 2014; 73 (05) 838-844.
11 Wallace DJ, Stohl W, Furie RA. et al A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1168-1178.